C11789: Unique Biosensor for Continuous Monitoring of Circulating BiomarkersNovelty:
The technology presents a novel transistor-based biosensor design for continuous monitoring of circulating biomarkers in blood or urine that can be used for clinical diagnosis, point of care (POC) assays, and patient monitoring.
Value Proposition:
There is currently no method to measure proteins, molecules, and drugs in bodily fluids with immediate feedback. The technology involves a novel biosensor design for continuously monitoring body fluids to detect and quantify proteins, molecules, metabolites, drugs, electrolytes or enzyme or drug function. This invention will aid healthcare professionals in predicting survival, stroke, seizures, and neuromotor outcomes for example. The device can potentially be used in renal dialysis circuits, urine drainage catheters, ECMO, VAD, or cardiopulmonary bypass to provide immediate feedback on biomarker levels. Advantages of this invention include:
• Continuous monitoring of levels of organ injury proteins, organ byproducts or metabolites, biomarkers of organ function or measures of anticoagulation to improve safety and decrease morbidity
• Placement in line with a blood-filled circuit minimizes blood loss, decreases the need for blood transfusions, and decreases the risk of infection and embolism
• Diagnostic(s)/prognostic(s) can be used in infants, children, and adults having heart surgery, ECMO, VAD or invasive urine drainage allowing improved monitoring, earlier diagnosis, and intervention for improved outcomes
Technical Details:
Johns Hopkins researchers have developed a biosensor design involving an electrical transistor-based platform. Water-stable semiconductors have the capability for covalent attachment of capture reagents to positions on the device where electrical signaling of binding events will be strong. Multiple transistors with contrasting responses to factor binding are linked to produce logic elements and binary, selective, and low-noise outputs for immediate feedback.
Looking for Partners:
To develop and commercialize the technology as a continuous monitoring biosensor for use in diagnosis or patient care.
Stage of Development:
Preclinical
Data Availability:
Under CDA/NDA
Publications/Associated Cases:
Biosensor Aims To Detect Brain Injuries During Heart Surgery
